BiotechTube
Sylentis

Sylentis

Madrid, Spain· Est.
sylentis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

Sylentis is a clinical-stage biotechnology company pioneering RNAi-based therapies for ocular diseases. The company leverages its proprietary SirFinder™ AI-driven platform to design highly specific siRNA compounds, with a pipeline led by tivanisiran for dry eye disease and SYL1801 for age-related macular degeneration (AMD). As a subsidiary of PharmaMar, Sylentis operates with a dual business model, advancing its own therapeutic pipeline while also offering CDMO and partnership services for external RNAi drug development.

Ophthalmology

Technology Platform

Proprietary AI-driven software SirFinder™ for the rational design of highly specific and efficient siRNA compounds for gene silencing.

Funding History

3
Total raised:$60M
Series C$30M
Series B$20M
Series A$10M

Opportunities

The global markets for dry eye disease and age-related macular degeneration are multi-billion dollar opportunities with significant unmet need.
Positive Phase IIa data for SYL1801 in AMD validates the platform and creates potential for high-value partnerships.
The company's CDMO services offer a parallel revenue stream by leveraging its RNAi expertise for external clients.

Risk Factors

Clinical development risk remains high, as both lead candidates must succeed in larger, pivotal trials.
The ophthalmology competitive landscape is intense, requiring clear differentiation from existing therapies.
As a subsidiary, the company's strategy and funding are dependent on the continued commitment of its parent company, PharmaMar.

Competitive Landscape

In dry eye disease, Sylentis's tivanisiran competes with a range of anti-inflammatories, immunosuppressants, and newer biologic therapies. In AMD, SYL1801 would enter a market dominated by anti-VEGF injections (e.g., aflibercept, ranibizumab, bevacizumab) and newer extended-duration therapies, requiring it to demonstrate a superior or complementary mechanism of action to gain traction.

More companies in RNA Therapeutics (non-mRNA) →More companies in Spain →